drugset
drugset / Trial / NCT07676903

A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors

NCT07676903 ↗

Phase 1 Not yet recruiting 170 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of SHR-4685 in participants with advanced solid tumors.

Timeline

Start
2026-07
Primary completion
2028-10
Completion
2028-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-4685 Unknown — —

Indications

neoplasm